Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
BridgeBio Pharma, Inc.
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
June 28, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
June 22, 2026
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 27, 2026
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
May 12, 2026
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
May 11, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 8, 2026
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
May 7, 2026
BridgeBio to Participate in May and June Investor Conferences
May 6, 2026
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
May 6, 2026
1
2
3
Next Page
→